EP0857483A1 — Substituted aminopyridines in the treatment of glucose metabolism disorders
Assigned to Eli Lilly and Co · Expires 1998-08-12 · 28y expired
What this patent protects
The present invention provides a method of inhibiting glucose metabolism deterioration in a mammal by administering a substituted aminopyrimidine having the Formula wherein R 1 , R 2 , and R 3 are, independently, hydrogen, halogen, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, …
USPTO Abstract
The present invention provides a method of inhibiting glucose metabolism deterioration in a mammal by administering a substituted aminopyrimidine having the Formula wherein R 1 , R 2 , and R 3 are, independently, hydrogen, halogen, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkyl, or C 3 -C 5 -cycloalky; R 4 is hydrogen, formyl, acetyl, propionyl or butyryl; provided that R 1 , R 2 and R 3 are not all hydrogen at the same time; or a pharmaceutically acceptable salt or solvate thereof.
Drugs covered by this patent
- Velsipity (Etrasimod Arginine) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.